<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411931</url>
  </required_header>
  <id_info>
    <org_study_id>MH 119</org_study_id>
    <nct_id>NCT00411931</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetics Study of MultiHance in Pediatric Patients</brief_title>
  <official_title>A Clinical Investigation of the Pharmacokinetics and Safety of MultiHance in Patients From 2-5 Years of Age Undergoing A Clinical Indicated MRI of the CNS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bracco Diagnostics, Inc</source>
  <brief_summary>
    <textblock>
      Compare relative exposure in the younger age group in order to supplement the PK profile
      already determined in older children and adults
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the blood PK of Multihance in patients from 2 to 5 years of age</measure>
    <time_frame>up to 24 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety of Multihance in patients from 2 to 5 years of age</measure>
    <time_frame>through 72 hours post dose</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Central Nervous System Pathology</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multihance</intervention_name>
    <description>0.5M administered as a single injection</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 2 and 5 years of age

          -  Obtained informed consent from patient's parent or guardian

          -  Obtain assent when applicable according to local law

          -  Known or suspected disease of the central nervous system (brain or spine)

          -  Referred for MRI of the brain or spine requiring an injection of an MR contrast agent

        Exclusion Criteria:

          -  Contraindications to MR examination

          -  Undergoing MRI in an emergency situation

          -  Known allergy to one or more ingredients in the contrast agent or history of
             hypersensitivity to gadolinium or metals

          -  Sickle cell anemia

          -  Likely to undergo an invasive examination within 72 hours after administration of the
             investigational product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianpaolo Pirovano, M. D.</last_name>
    <role>Study Director</role>
    <affiliation>Bracco Diagnostics, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2006</study_first_submitted>
  <study_first_submitted_qc>December 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2006</study_first_posted>
  <last_update_submitted>January 10, 2008</last_update_submitted>
  <last_update_submitted_qc>January 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Gianpaolo Pirovano, MD, Executive Director, Corporate Medical Development</name_title>
    <organization>Bracco Diagnostics, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

